for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kymera Therapeutics Inc

KYMR.OQ

Latest Trade

57.00USD

Change

1.68(+3.04%)

Volume

34,544

Today's Range

55.32

 - 

57.46

52 Week Range

29.94

 - 

91.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
55.32
Open
55.32
Volume
34,544
3M AVG Volume
7.06
Today's High
57.46
Today's Low
55.32
52 Week High
91.92
52 Week Low
29.94
Shares Out (MIL)
51.04
Market Cap (MIL)
2,823.52
Forward P/E
-32.11
Dividend (Yield %)
--

Next Event

Kymera Therapeutics Inc To Discuss Data From KT-474 Phase 1 Trial Call

Latest Developments

More

Kymera Therapeutics Inc Files For Mixed Shelf Size Not Disclosed

Kymera Therapeutics Says Richard Chesworth, Chief Scientific Officer, Will Be Departing Co Effective As Of October 22

Kymera Therapeutics Posts Qtrly Loss Per Share $0.55

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Its targeted protein degradation platform, Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. Its Pegasus platform, includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Proprietary Chemistry. Its therapeutic pipeline programs includes IRAK4, IRAKIMiD, and STAT3, which each focus on a single critical signaling node within the genetically and clinically validated interleukin-1 receptor/toll-like receptor ( IL-1R/TLR) and janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways.

Industry

Biotechnology & Drugs

Contact Info

200 Arsenal Yards Blvd.

Suite 230, 2Nd Floor

WATERTOWN, MA

02472

United States

+1.857.2855314

https://www.kymeratx.com/

Executive Leadership

Bruce L. Booth

Independent Chairman of the Board

Nello Mainolfi

President, Chief Executive Officer, Co-Founder, Director

Bruce N. Jacobs

Chief Financial Officer

Richard Chesworth

Chief Scientific Officer

Elaine Caughey

Chief Business Officer

Key Stats

1.91 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.1K
EPS (USD)

2020

-3.150

2021(E)

-1.734
Price To Earnings (TTM)
--
Price To Sales (TTM)
43.75
Price To Book (MRQ)
9.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.85
LT Debt To Equity (MRQ)
0.44
Return on Investment (TTM)
-25.17
Return on Equity (TTM)
-18.98

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up